Truly human antibody therapeutics.
Humans mount lasting antibody responses to infectious diseases and cancer. Abterra Bio uses next-generation sequencing, mass spectrometry, and machine learning to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.
Abterra Bio technology is built on decades of experience in antibody sequencing and analysis. Click on the services below to see how we can help you!
Get In Touch
Tell Us About Your Project.
Need more information? We’re here to answer any questions you have.
What Our Partners Are Saying About Us
I have had great experiences using Abterra Bio’s Reptor platform. The data generated was highly valuable, and the team provided quick and open communication throughout the whole process.
I would strongly recommend the services, Valens and Reptor, from Abterra Bio. Not only were the individuals extremely helpful throughout the development of my project, but they were always available to answer any questions I had throughout the project. Best of all, Abterra provided high-quality sequences with a rapid turnover which allowed my lab to continue our research with little delay.
Project Summary Next-generation sequencing of B cell populations (Rep-Seq) has become a powerful tool in immunology and antibody discovery. At Abterra Bio we developed Reptor, an integrated Rep-Seq...
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights...
Project Summary Phage display is a powerful toolkit for antibody discovery and engineering. In this study, we used phage display to identify Cas9-binding single domain (VHH) antibodies. In addition...